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Summary Blood samples were collected from 52 incident cases of histologically confirmed prostate cancer, an equal number of cases of
benign prostatic hyperplasia (BPH) and an equal number of apparently healthy control subjects. The three groups were matched for age and
town of residence in the greater Athens area. Steroid hormones, sex hormone-binding globulin, and insulin-like growth factor 1 (IGF-1) were
measured in duplicate by radioimmunoassay in a specialized US centre. Statistical analyses were performed using multiple logistical
regression. The results for IGF-1 in relation to prostate cancer and BPH were adjusted for demographic and anthropometric factors, as well
as for the other measured hormones. There was no relation between IGF-1 and BPH, but increased values of this hormone were associated
with increased risk of prostate cancer; an increment of 60 ng ml-' corresponded to an odds ratio of 1.91 with a 95% confidence interval of
1.00-3.73. There was also some evidence for an interaction between high levels of testosterone and IGF-1 in relation to prostate cancer. This
finding suggests that, in addition to testosterone, IGF-1 may increase the risk of prostate cancer in humans.
Insulin-like growth factor 1 (IGF-1) is secreted mainly by the liver
but is also produced in several other tissues in response to growth
hormone (LeRoith et al, 1992). It has been documented that IGF-1
can act in an autocrine and paracrine manner to promote normal
growth and malignant cellular proliferation (Daughaday, 1990;
LeRoith et al, 1992). The importance ofIGF-1 as a major growth-
regulating molecule has been established for cells in culture
(Goustin et al, 1986; LeRoith et al, 1992; Webster et al, 1996) and
has also been suggested by studies in vivo (Ezzat and Melmed,
1991). IGF-1 and several of its binding proteins are produced by
normal prostate cells (Cohen et al, 1991) as well as prostate cancer
cells (Pietrzjowski et al, 1993; Kimura et al, 1996) and act locally
through activation of IGF-1 receptors to stimulate cell prolifera-
tion (Angelloz-Nicoud and Binoux, 1995). In addition to its estab-
lished autocrine and paracrine action, IGF-1 has important
endocrine functions (LeRoith et al, 1992). However, the role, if
any, of circulating IGF-1 in the aetiology of benign prostatic
hyperplasia (BPH) and prostate cancer has not received sufficient
attention.
We havepreviously reported results concerning the role ofserum
steroid hormones in the aetiology ofBPH (Lagiou et al, 1997) and
prostate cancer (Signorello et al, 1997) from a matched
case-control study undertaken in Athens, Greece. Circulating IGF-
1 was measured in the same sera, and we present the relevant
results in this report.
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SUBJECTS AND METHODS
In the context of a large, ongoing case-control study of diet in
relation to prostate cancer and BPH, blood samples were collected
during an 18-months period from 52 incident cases of histologi-
cally confirmed prostate cancer and 52 cases of BPH with
matching for age (±1 year) and town of residence within the
greater Athens area. Within the constraints imposed by this
matching, cases of prostate cancer and BPH were randomly
selected from among those enrolled in the larger study.
In order to choose appropriate controls, we identified day-care
centres for the elderly that exist throughout the urban centres of
Greece (KAPI). In these centres, healthy, elderly people meet for
social interaction and entertainment. We approached attendees at
KAPI centres in the same or neighbouring towns as those of the
matched cancer/BPH pairs. One control was randomly selected for
each matched cancer/BPH pair, again with matching for age
within 1 year. Among the eligible controls, fewerthan ten declined
to participate and were replaced. In addition to blood, all study
participants provided information on their exact age, height,
weight and years ofschooling.
Frozen serum samples were shipped from Athens to Beth Israel
Hospital in Boston, USA, packed in dry ice. The coded samples
arrived unthawed and in good condition and were analysed
without knowledge ofcase-control status by laboratory personnel
under the supervision of one ofthe investigators (CSM).
IGF- 1 concentrations were measured, afterethanol extraction, by
a commercially available radioimmunoassay kit (Nichols Institute,
San Juan Capistrano, CA, USA). Testosterone (T), oestradiol (E2),
and dehydroepiandrosterone sulphate (DHEAS) were measured
by commercially available radioimmunoassay kits (Diagnostic
Products, Los Angeles, CA, USA), and sex hormone-binding glob-
ulin (SHBG) concentrations were determined by a commercially
available enzyme-linked immunosorbent assay (ELISA) (Wallac,
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Table 1 Distribution of 52 cases of incident prostate cancer, 52 cases of incident benign prostatic hyperplasia (BPH),
and 52 healthy controls by age, years of schooling, and anthropometric variables
Variable Prostate cancer BPH Controls
n(%) n(%) n(%)
Age (years)
<69 20 (38.5) 18 (34.6) 21 (40.4)
70-74 18 (34.6) 19 (36.5) 17 (32.7)
.75 14 (26.9) 15 (28.9) 14 (26.9)
Years of schooling
0-5 12 (23.1) 11 (21.2) 15 (28.9)
6 15 (28.9) 12 (23.1) 20 (38.5)
7-11 12 (23.1) 11 (21.2) 11 (21.2)
>12 13 (25.0) 18 (34.6) 6 (11.5)
Height (cm)
<165 8 (15.4) 4 (7.7) 16 (30.8)
165-169 12 (23.1) 18 (34.6) 13 (25.0)
170-174 12 (23.1) 14 (26.9) 14 (26.9)
.175 20 (38.5) 16 (30.8) 9 (17.3)
Weight (kg)
<70 13 (25.0) 14 (26.9) 13 (25.0)
70-79 21 (40.4) 21 (40.4) 17 (32.7)
80-89 12 (23.1) 12(23.1) 16(30.8)
.90 6 (11.5) 5 (9.6) 6 (11.5)
Body mass index (kg m-2)
<24 13 (25.0) 17 (32.7) 13 (25.0)
24-26.99 20 (38.5) 14 (26.9) 11 (21.2)
27-29.99 11 (21.2) 18 (34.6) 20 (38.5)
.30 8 (15.4) 3 (5.8) 8 (15.3)
Table 2 Spearman correlation coefficients between the measured hormones among healthy controls
IGF-1 Testosterone DHT SHBG DHEAS
IGF-1 - - -
Testosterone 0.10
DHT 0.03 0.34a
SHBG -0.15 0.60a 0.38a -
DHEAS 0.37a 0.28a 0.34a -0.02
Oestradiol -0.01 0.31a 0.27a 0.11 0.38a
aP-value <0.05; IGF-1, insulin-like growth factor 1; SHBG, sex hormone-binding globulin; DHT, dihydrotestosterone; DHEAS,
dehydroepiandrosterone sulphate.
Gaithersburg, MD, USA). Dihydrotestosterone (DHT) concentra-
tions were measured, after extraction, using commerically avail-
able radioimmunoassay kits (DSL International, TX, USA). All
hormones were measured in duplicate, and the average of the two
measurements for each hormone was used for data analyses. The
sensitivities ofthe assays used were as follows: IGF-1, 13 ng ml-l
T, 4.0 ng dl-; E2, 2.0 pg ml-'; SHBG, 0.5 nmol 1-1; DHT,
4.0 pg ml-'; DHEAS, 1.1 mg dl-'. The intra-assay coefficients of
variation were as follows: IGF-1, 2.4-3.0%; T, 4.0-7.0%; E2,
4.0-5.0%; SHBG, 1.4-1.8%; DHT, 3.1-6.2%; DHEAS, 6.0-9.8%.
No significant cross-reactivity exists between the measured
hormones. Cross-reactivity between IGF-l and IGF-2 with the anti-
serum used in this assay has been shown to be 0.5%, whereas there
is virtually no cross-reactivity between IGF-1 and other peptide
hormones. IGF-1-binding proteins were removed through the
extraction method before measuring IGF-1.
For the analyses, cases with prostate cancer and BPH cases were
alternatively compared with the healthy controls. Statistical
analyses were performed using stratification and modelling of the
data by multiple logistic regression (Breslow and Day, 1980).
Conditional and unconditional models were essentially identical.
All P-values are two-tailed. The STATA statistical package (Stata
Corporation, College Station, TX, USA) was used throughout.
RESULTS
Table 1 presents descriptive demographical and anthropometrical
measures of study participants in each of the three groups. These
factors have been adjusted, using multiple logistic regression, in the
evaluation of the hormonal correlates ofprostate cancer and BPH.
Table 2 shows Spearman correlation coefficients of the five
hormones studied and SHBG in the controls. The associations
between IGF-1, on the one hand, and the remaining five factors, on
the other, are not strong, with the possible exception of that with
DHEAS. Of particular interest is the lack of association between
IGF-I and DHT, because several of the BPH patients as well as
some ofthe prostate cancerpatients who hadcoexisting BPH could
have taken in the past (despite exclusion protocol requirements)
finasteride (a 5 x-reductase inhibitor that blocks the conversion
ofT to DHT).
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Table 3 Mean value and standard error (SE) of steroid hormones and SHBG in the three study series
Hormone Prostate cancer BPH Controls
mean (SE) mean (SE) mean (SE)
Testosterone (ng dl-1) 447.1 (38.4) 480.1 (30.0) 541.8 (27.2)
Oestradiol (pg ml-') 11.0 (3.6) 7.9 (1.3) 22.5 (2.5)
DHT (pg ml-1) 161.8 (20.5) 180.6 (21.3) 634.9 (59.5)
DHEAS (gg dl-1) 114.9 (11.7) 123.7 (12.6) 110.5 (8.6)
SHBG (nmol 1-1) 53.8 (2.4) 56.9 (3.4) 58.3 (3.3)
BPH, benign prostatic hyperplasia; DHT, dihydrotestosterone; DHEAS, dehydroepiandrosterone sulphate; SHBG, sex
hormone-binding globulin.
Table 4 Frequency distribution of incident cases of prostate cancer, benign prostatic hyperplasia (BPH) and healthy controls by
marginal quartiles of IGF-1
Quartiles of IGF-1a
Variable n Mean (SD) 1 2 3 4 P-value for linear trendb (unadjusted)
(n) (n) (n) (n)
IGF-1 (ng ml-')
Prostate cancer 51 160.3 (68.2) 8 13 13 17 0.01
BPH 50 146.0 (68.2) 13 10 16 11 0.13
Controls 52 124.7 (58.6) 17 18 8 9
aQl, <92.3; Q2, 92.4-135.0, Q3, 135.1-184.5; Q4, >184.5; bcompared with controls. IGF-1, insulin-like growth factor 1.
Table 5 Multiple logistic regression - derived adjusted odds ratios for prostate cancer and benign prostatic
hyperplasia (BPH) by specified increment of IGF-1
IGF-1 ORcrude ORa ORb 95% CPb P.valueb
IGF-1 (per 60 ng ml-1 increment)
Prostate cancer vs control subjects 1.71 1.52 1.91 (1.00, 3.73) 0.05
BPH vs control subjects 1.38 1.23 0.99 (0.48, 2.06) 0.99
aAdjusted for age, height, body mass index, and years of schooling; badjusted for age, height, body mass index,
years of schooling, SHBG and the four hormones listed in Table 3. IGF-1, insulin-like growth factor 1.
Table 3 presents a summary of the results that have been sepa-
rately reported concerning levels ofsteroid hormones and SHBG in
the three study series. In these data, after adjusting for age, height,
body mass index, education and mutually among the hormones and
SHBG, cases ofprostate cancer were found to have higher levels of
T (P = 0.07), lower levels of DHT (P < 0.001) and no remarkable
differences in levels of E2 and SHBG compared with the healthy
control subjects. Cases ofBPH were observed to have higher levels
of DHEAS (P = 0.01), but no significant difference in levels of
SHBG, T, or E2 when compared with the same control subjects.
Tables 4 and 5 present the principal results of this study that
focus on IGF-1. The crude analysis in Table 4 indicated that IGF-1
levels are substantially higher among patients with prostate cancer
in comparison with controls, whereas among patients with BPH
the elevation of IGF-1 is smaller and non-significant. After
adjusting for demographical and anthropometrical risk factors
as well as for the other hormones, the association between IGF-1
and prostate cancer is strengthened and remains statistically
significant. In contrast, the weak association between IGF-1 and
BPH disappears after adjustment for the same set of confounders
(Table 5).
Among the steroid hormones that have been investigated in rela-
tion to prostate cancer, T stands out on the basis ofquality-adjusted
empirical evidence and biomedical credibility. Therefore, we evalu-
ated whetherT and IGF-1 may interact in relation to prostate cancer.
We usedmedian values ofIGF-I and Tin the combined distribution
of prostate cancer cases and controls to create four groups, using
subjects with low values of both IGF-1 and T as the reference
for categorical contrasts. The odds ratios (95% CI) were: 1.30
(0.19-8.86) for subjects with high T and low IGF-1; 2.97
(0.46-19.06) for subjects with low T and high IGF-1; 6.86
(0.75-62.56) forsubjects with highTandhigh IGF-1. Itappears that
there may be an interaction ofhigh levels ofboth IGF-I and Tin the
causation ofprostate cancer ifthe associations are indeed causal.
DISCUSSION
There is circumstantial evidence that androgens play a role in the
aetiology ofprostate cancer and BPH. Androgens are essential for
the growth and function of the prostate and can produce prostate
cancer and BPH in experimental animals (Goustin et al, 1986;
Webster et al, 1996). T is the dominant stimulus for prostatic
British JournalofCancer (1997) 76(9), 1115-1118 0 CancerResearch Campaign 19971118 CS Mantzoros etal
growth, whereas adrenal androgens, including DHEAS and
androstendione, are weaker androgens that can be converted to
more potent ones (T and DHT) in several tissues including the
prostate (Montie and Pienta, 1994; Geller, 1995). DHT, a hormone
produced by reduction of T by 5 oc-reductase, is the most potent
intracellular androgen, but it is the intraprostatic rather than the
circulating DHT that affects prostate growth (Geller, 1993; Montie
and Pienta, 1994; Geller, 1995).
With respect to IGF-1, the evidence that implicates it in the aeti-
ology ofcancer ofthe prostate derives mostly from in vitro studies
and pathophysiological considerations. Normal and malignant
prostate cells produce IGF-1 and several of its binding proteins
that can act in a paracrine or autocrine manner (Cohen et al, 1991;
Pietrzjowski et al, 1993; Kimura et al, 1996). IGF-binding proteins
are found abundantly in prostate secretions, and their serum levels
have been reported to differ between patients with and without
prostate cancer (Cohen et al, 1993; Kanety et al, 1993). Moreover,
prostate cells express IGF-1 receptors and are very sensitive to
stimulation by IGFs (Cohen et al, 1991; Kimura et al, 1996). In
vitro activation of IGF-1 receptors induces proliferation of
prostate cancer cells that is directly dependent on IGF availability
and is modulated by IGF-binding proteins (Angelloz-Nicoud and
Binoux, 1995). In addition, antisense RNA to IGF-1 receptor
suppresses tumour growth and prevents invasion by rat prostate
cancer cells in vivo (Burfeind et al, 1996). Finally, suramin, a drug
that inhibits prostate cancer growth and is now being tested in clin-
ical trials for prostate cancer, is thought to act, at least in part, by
decreasing serum levels ofIGF-1 and 2 (Miglietta et al, 1993).
There is scarce epidemiological literature concerning IGF-1 in
relation to cancer in general and, to our knowledge, no epidemio-
logical study has been published reporting on the relationship
between IGF-1 and prostate cancer or BPH. Our findings suggest
that IGF-1 may play a role in the aetiology ofprostate cancer. This
interpretation is strengthened by the lack of association between
IGF-1 and BPH. Moreover, pathophysiological considerations and
experimental evidence impart an element ofbiomedical credibility
in the causal link between IGF-1 and prostate cancer. Suggestive
evidence that IGF-1 may play a causal role in breast cancer
(Weiderpass et al, 1997) can also be thought of as supportive for a
similar link with respect to prostate cancer.
A straightforward causal interpretation is hindered by a number
of considerations. Case-control investigations cannot satisfy the
time sequence criterion forcausality and cannot directly address the
concern that the disease may alter levels of the hormones under
investigation. Moreover, the present study is relatively small and
statistical significance is not a guarantee that chance did not
contribute to the generation of results. In addition, interrelations
between serum hormone levels and recognized orunsuspected feed-
back mechanisms may contribute to residual confounding ofunpre-
dictable magnitude and direction. Finally, the strikingly reduced
DHT levels in cases with prostate cancer and BPH, possibly a result
ofunreported 5 ox-reductase inhibitor use by some patients, justifies
concern, even although IGF-I was unrelated to DHT in controls or,
indeed, in subjects in any ofthe three study groups.
In conclusion, the results of the present study raise the possi-
bility that IGF-1 may increase the risk of prostate cancer but
provide no evidence that this hormone plays a role in the aetiology
of BPH. The evidence of interaction between IGF-1 and T with
respect to prostate cancer is statistically weak (P = 0.09), but it is
biologically credible and offers additional opportunities for evalu-
ating the hypotheses that emerge from these data.
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